Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 6/20 | 0.34 |
| ▸ | CCR5 | P51681 | 4/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25340719 | 0.93 | GHSR (0.34) | RORCGHSRLTA4HPDE4B | |
| SCHEMBL29626362 | 0.85 | HTR2A (0.35) | HTR2ACCR5CA1CA2ACHE | |
| SCHEMBL29132480 | 0.85 | HTR2A (0.38) | HTR2ACCR5CA1CA2ACHE | |
| SCHEMBL29132505 | 0.85 | HTR2A (0.38) | HTR2ACCR5CA1CA2ACHE | |
| SCHEMBL29626276 | 0.85 | HTR2A (0.38) | HTR2ACCR5CA1CA2ACHE | |
| SCHEMBL29626307 | 0.83 | HTR2A (0.34) | RORCHTR2ACCR5CA1CA2 | |
| SCHEMBL29626448 | 0.81 | TRPM8 (0.38) | HTR2ACCR5CA1CA2ACHE | |
| SCHEMBL29132495 | 0.79 | CCR5 (0.38) | HTR2ACCR5CA1CA2ACHE | |
| SCHEMBL29626434 | 0.78 | HTR2A (0.34) | HTR2ACCR5CA1CA2ACHE | |
| SCHEMBL25338313 | 0.78 | TRPM8 (0.40) | HTR2ACCR5CA1CA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122160-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2025-04-17 | — | — | US | disclosed |
| CN-116829555-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-4211122-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Calico Life Sciences LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2022056281-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122160-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN1, PTPN2, PTPN18 | RORC 1878/4885HTR2A 2663/4885CCR5 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.